HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Teva UK Enters Erectile Dysfunction Category With First Ever Rx-To-OTC Switch

Executive Summary

Teva UK's first Rx-to-OTC switch is a UK Viagra Connect sildenafil competitor under the Liberize brand. Priced around 25% lower than the market leader, Teva's new brand must also compete with Perrigo's white label and Dr Reddy's Almus branded alternatives within the country's growing erectile dysfunction category. 

You may also be interested in...



German Rx-To-OTC Switch Committee To Consider Sildenafil Reclassification

Rx-to-OTC switches of sildenafil and xylometazoline and ipratropium bromide combinations are on the cards for January's meeting of the German Expert Committee for Prescription.

Pfizer's Upjohn Breaking The Silence Around ED With New Viagra Connect Campaign In UK

Pfizer is investing roughly $10m in Viagra Connect in the UK to help raise awareness of erectile problems among the country's male population. 

Perrigo To Launch UK Private-Label Viagra Connect Competitor

Perrigo is launching in the UK an OTC sildenafil generic to compete with Pfizer's erectile dysfunction drug Viagra Connect. 

Topics

UsernamePublicRestriction

Register

RS151852

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel